Clinical Trials Browser

NCT04670016 2026-04-15

HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers

Completed

20 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Radiation Injuries, Recurrence

NCT01445288 2026-04-14

Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

Completed

76 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Medulloblastoma, Central Nervous System Neoplasms, Germinoma, Neuroectodermal Tumors, Primitive, Neurotoxicity Syndromes

NCT02359565 2026-04-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Phase 1 Active not recruiting

71 enrolled

CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT04185038 2026-04-13

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Phase 1 Recruiting

90 enrolled

CNS

Choroid Plexus Carcinoma, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioma, Medulloblastoma, Neoplasms, Germ Cell and Embryonal, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT05278208 2026-04-13

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Phase 1/2 Recruiting

65 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioma, Medulloblastoma, Meningioma, Neoplasms, Germ Cell and Embryonal, Central Nervous System Neoplasms

NCT06465199 2026-04-13

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Phase 1/2 Recruiting

289 enrolled

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT05096481 2026-04-08

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Phase 2 Recruiting

120 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Medulloblastoma

NCT07206849 2026-04-08

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

Phase 2 Not yet recruiting

79 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Glioma

NCT03033992 2026-04-06

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

Phase NA Active not recruiting

80 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioma

NCT04978727 2026-04-06

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Phase 1 Active not recruiting

35 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Ependymoma, Glioblastoma, Medulloblastoma, Oligodendroglioma

NCT05839379 2026-03-31

Targeted Pediatric High-Grade Glioma Therapy

Recruiting

350 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT07501156 2026-03-30

H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

Phase 1/2 Recruiting

30 enrolled

CNS

Diffuse Intrinsic Pontine Glioma

NCT03605550 2026-03-27

A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

Phase 1 Active not recruiting

64 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT06838676 2026-03-27

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Phase 2 Recruiting

60 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT05843253 2026-03-20

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Phase 2 Recruiting

120 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT03478462 2026-03-18

CLOVER-2

Phase 1 Active not recruiting

30 enrolled

CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04655404 2026-03-18

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

Phase EARLY_PHASE1 Recruiting

15 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT04943848 2026-03-17

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Phase 1 Recruiting

36 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT01165333 2026-03-16

CILENT

Phase 1 Completed

32 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Phase EARLY_PHASE1 Recruiting

15 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

NCT06639607 2026-03-10

PRiME II

Phase 1/2 Not yet recruiting

68 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT04837547 2026-03-09

PEACH

Phase 1 Active not recruiting

24 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Neuroblastoma

NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Phase 1/2 Completed

47 enrolled 36 charts

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT07076498 2026-02-25